Northwest Biotherapeutics (OTCMKTS:NWBO) Announces Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) released its quarterly earnings data on Friday. The biotechnology company reported ($18.22) EPS for the quarter, Zacks reports.

Northwest Biotherapeutics Stock Down 1.3%

Shares of OTCMKTS:NWBO traded down $0.00 during trading on Friday, reaching $0.24. 2,961,807 shares of the company’s stock traded hands, compared to its average volume of 3,367,632. Northwest Biotherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $0.48. The company has a 50-day simple moving average of $0.24 and a 200-day simple moving average of $0.26. The firm has a market cap of $369.04 million, a PE ratio of -4.00 and a beta of -0.56.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.